| Total | Expression | p-value | |
---|---|---|---|---|
High | Low | |||
(N = 388) | (N = 193) | (N = 195) | ||
Gender | ||||
female | 177 (45.6%) | 81 (42.0%) | 96 (49.2%) | 0.182 |
male | 211 (54.4%) | 112 (58.0%) | 99 (50.8%) | Â |
Age (years) | ||||
 >  = 60 | 279 (71.9%) | 135 (69.9%) | 144 (73.8%) | 0.459 |
 < 60 | 109 (28.1%) | 58 (30.1%) | 51 (26.2%) |  |
M | ||||
M0 | 292 (75.3%) | 137 (71.0%) | 155 (79.5%) | 0.034 |
M1 | 58 (14.9%) | 38 (19.7%) | 20 (10.3%) | Â |
MX | 38 (9.8%) | 18 (9.3%) | 20 (10.3%) | Â |
N | ||||
N0 | 224 (57.7%) | 88 (45.6%) | 136 (69.7%) |  < 0.001 |
N1 | 93 (24.0%) | 57 (29.5%) | 36 (18.5%) | Â |
N2 | 71 (18.3%) | 48 (24.9%) | 23 (11.8%) | Â |
T | ||||
T1 | 11 (2.8%) | 4 (2.1%) | 7 (3.6%) | 0.003 |
T2 | 60 (15.5%) | 18 (9.3%) | 42 (21.5%) | Â |
T3 | 274 (70.6%) | 144 (74.6%) | 130 (66.7%) | Â |
T4 | 43 (11.1%) | 27 (14.0%) | 16 (8.2%) | Â |
Stage | ||||
Stage I | 59 (15.2%) | 16 (8.3%) | 43 (22.1%) |  < 0.001 |
Stage II | 159 (41.0%) | 70 (36.3%) | 89 (45.6%) | Â |
Stage III | 111 (28.6%) | 69 (35.8%) | 42 (21.5%) | Â |
Stage IV | 59 (15.2%) | 38 (19.7%) | 21 (10.8%) | Â |